Abstract
The study was aimed to evaluate the safety and efficacy of cell therapy using autologous menstrual blood derived- mesenchymal stromal cells (Men-MSCs) in fertility potential of poor ovarian responders (PORs). POR women were divided into mesenchymal stroma cell (MSC) therapy (n = 15) and routine ICSI (n = 16) groups. The cultured Men-MSCs were autologously injected into left ovary of MSC group after approval by flow cytometry, karyotyping, endotoxin, sterility and mycoplasma tests. Changes in anti-Mullerian hormone (AMH), antral follicles count (AFC), oocytes and embryos number, clinical pregnancy rate and live birth rate were followed in both groups up to one year after treatment. 4 of 15 participants in MSC group got naturally pregnant during 3 months after cell administration, in contrast to no natural conception in control group (P = 0.04). The mean AMH level did not significantly differ with that of previous cycle or control group. Although mean AFC and oocytes number in MSC group did not indicate considerable difference with those of control group, raise of these parameters in comparison with previous cycle was significant (both P = 0.01). Nonetheless, oocyte fertilization rate and embryo number in MSC group were higher than control group (P = 0.04 and P = 0.008, respectively). Altogether, 7 of 15 women in MSC group and 2 of 16 women in routine ICSI group had clinical pregnancy that resulted in 5 live births in main group and one birth in control group. In conclusion, cell therapy using Men-MSCs could be considered as a potential treatment to restore fertility capability of POR women.
The trial registration number (TRN): IRCT20180619040147N2.
Date of registration: 2018-08-21.
Similar content being viewed by others
References
Devine, K., Mumford, S. L., Wu, M., DeCherney, A. H., Hill, M. J., & Propst, A. (2015). Diminished ovarian reserve in the United States assisted reproductive technology population: Diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. Fertility and Sterility, 104(3), 612–619.
Papathanasiou, A., Searle, B. J., King, N. M., & Bhattacharya, S. (2016). Trends in ‘poor responder’research: Lessons learned from RCTs in assisted conception. Human Reproduction Update, 22(3), 306–319.
Ferraretti, A., La Marca, A., Fauser, B., Tarlatzis, B., Nargund, G., Gianaroli, L., & ESHRE working group on Poor Ovarian Response Definition. (2011). ESHRE consensus on the definition of ‘poor response' to ovarian stimulation for in vitro fertilization: The Bologna criteria. Human Reproduction, 26(7), 1616–1624.
Humaidan, P., Alviggi, C., Fischer, R., & Esteves, S. C. (2016). The novel POSEIDON stratification of ‘low prognosis patients in assisted reproductive Technology’and its proposed marker of successful outcome. F1000Research, 23(5), 2911.
Kyrou, D., Kolibianakis, E. M., Venetis, C. A., Papanikolaou, E. G., Bontis, J., & Tarlatzis, B. C. (2009). How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: A systematic review and meta-analysis. Fertility and Sterility, 91(3), 749–766.
Alsbjerg, B., Haahr, T., Elbaek, H. O., Laursen, R., Povlsen, B. B., & Humaidan, P. (2019). Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders–a case series. Reproductive Biomedicine Online, 38(5), 677–682.
Lin, L.-T., Vitale, S. G., Chen, S.-N., Wen, Z.-H., Tsai, H.-W., Chern, C.-U., & Tsui, K.-H. (2018). Luteal phase ovarian stimulation may improve oocyte retrieval and oocyte quality in poor ovarian responders undergoing in vitro fertilization: Preliminary results from a single-center prospective pilot study. Advances in Therapy, 35(6), 847–856.
Kuroda, K., Kitade, M., Kumakiri, J., Jinushi, M., Shinjo, A., Ozaki, R., Ikemoto, Y., Katoh, N., & Takeda, S. (2016). Minimum ovarian stimulation involving combined clomiphene citrate and estradiol treatment for in vitro fertilization of Bologna-criteria poor ovarian responders. Journal of Obstetrics and Gynaecology Research, 42(2), 178–183.
Chern, C. U., Tsui, K. H., Vitale, S. G., Chen, S. N., Wang, P. H., Cianci, A., Tsai, H. W., Wen, Z. H., & Lin, L. T. (2018). Dehydroepiandrosterone (DHEA) supplementation improves in vitro fertilization outcomes of poor ovarian responders, especially in women with low serum concentration of DHEA-S: A retrospective cohort study. Reproductive Biology and Endocrinology, 16(1), 90.
Zhang, M., Niu, W., Wang, Y., Xu, J., Bao, X., Wang, L., Du, L., & Sun, Y. (2016). Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: A systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics, 33(8), 981–991.
Noventa, M., Vitagliano, A., Andrisani, A., Blaganje, M., Viganò, P., Papaelo, E., Scioscia, M., Cavallin, F., Ambrosini, G., & Cozzolino, M. (2019). Testosterone therapy for women with poor ovarian response undergoing IVF: A meta-analysis of randomized controlled trials. Journal of Assisted Reproduction and Genetics, 36(4), 673–683.
Li, X. L., Wang, L., Lv, F., Huang, X. M., Wang, L. P., Pan, Y., & Zhang, X. M. (2017). The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis. Medicine (Baltimore), 96(12), e6443.
Cai, M. H., Liang, X. Y., Wu, Y. Q., Huang, R., & Yang, X. (2019). Six-week pretreatment with growth hormone improves clinical outcomes of poor ovarian responders undergoing in vitro fertilization treatment: A self-controlled clinical study. Journal of Obstetrics and Gynaecology Research, 45(2), 376–381.
Gao, L., Huang, Z., Lin, H., Tian, Y., Li, P., & Lin, S. (2019). Bone marrow mesenchymal stem cells (BMSCs) restore functional endometrium in the rat model for severe Asherman syndrome. Reproductive Sciences, 26(3), 436–444.
Tan, J., Li, P., Wang, Q., Li, Y., Li, X., Zhao, D., Xu, X., & Kong, L. (2016). Autologous menstrual blood-derived stromal cells transplantation for severe Asherman's syndrome. Human Reproduction, 31(12), 2723–2729.
He, Y., Chen, D., Yang, L., Hou, Q., Ma, H., & Xu, X. (2018). The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Research & Therapy, 9(1), 263.
Lu, X., Cui, J., Cui, L., Luo, Q., Cao, Q., Yuan, W., & Zhang, H. (2019). The effects of human umbilical cord-derived mesenchymal stem cell transplantation on endometrial receptivity are associated with Th1/Th2 balance change and uNK cell expression of uterine in autoimmune premature ovarian failure mice. Stem Cell Research & Therapy, 10(1), 214.
Liu, R., Zhang, X., Fan, Z., Wang, Y., Yao, G., Wan, X., Liu, Z., Yang, B., & Yu, L. (2019). Human amniotic mesenchymal stem cells improve the follicular microenvironment to recover ovarian function in premature ovarian failure mice. Stem Cell Research & Therapy, 10(1), 299.
Edessy, M., Hosni, H. N., Shady, Y., Waf, Y., Bakr, S., & Kamel, M. (2016). Autologous stem cells therapy, the first baby of idiopathic premature ovarian failure. Acta Medica International, 3(1), 19–23. https://doi.org/10.5530/ami.2016.1.7.
Herraiz, S., Romeu, M., Buigues, A., MartÃnez, S., DÃaz-GarcÃa, C., Gómez-SeguÃ, I., MartÃnez, J., Pellicer, N., & Pellicer, A. (2018). Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertility and Sterility, 110(3), 496–505.
Chen, L., Qu, J., & Xiang, C. (2019). The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Research & Therapy, 10(1), 1.
Fathi-Kazerooni, M., Tavoosidana, G., Taghizadeh-Jahed, M., Khanjani, S., Golshahi, H., Gargett, C. E., Edalatkhah, H., & Kazemnejad, S. (2017). Comparative restoration of acute liver failure by menstrual blood stem cells compared with bone marrow stem cells in mice model. Cytotherapy, 19(12), 1474–1490.
Wang, Z., Wang, Y., Yang, T., Li, J., & Yang, X. (2017). Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Research & Therapy, 8(1), 11.
Manshadi, M. D., Navid, S., Hoshino, Y., Daneshi, E., Noory, P., & Abbasi, M. (2019). The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure. Microscopy Research and Technique, 82(6), 635–642.
Lai, D., Wang, F., Yao, X., Zhang, Q., Wu, X., & Xiang, C. (2015). Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure. Journal of Translational Medicine, 13(1), 155.
European Pharmacopoeia. (2018). European directorate for the quality of medicines & healthcare (EDQM). France: Strasbourg.
Musina, R., Belyavski, A., Tarusova, O., Solovyova, E., & Sukhikh, G. (2008). Endometrial mesenchymal stem cells isolated from the menstrual blood. Bulletin of Experimental Biology and Medicine, 145, 539–543.
Cui, C.-H., Uyama, T., Miyado, K., Terai, M., Kyo, S., Kiyono, T., & Umezawa, A. (2007). Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Molecular Biology of the Cell, 18(5), 1586–1594.
Khanjani, S., Khanmohammadi, M., Zarnani, A.H., Akhondi, M.M., Ahani, A., Ghaempanah, Z., Naderi, M.M., Eghtesad, S., and Kazemnejad, S. (2014). Comparative evaluation of differentiation potential of menstrual blood- versus bone marrow-derived stem cells into hepatocyte-like cells. PLoS one, 5;9(2):e86075.
Hida, N., Nishiyama, N., Miyoshi, S., Kira, S., Segawa, K., Uyama, T., Mori, T., Miyado, K., Ikegami, Y., & Cui, C. (2008). Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells, 26, 1695–1704.
Meng, X., Ichim, T. E., Zhong, J., Rogers, A., Yin, Z., Jackson, J., Wang, H., Ge, W., Bogin, V., & Chan, K. W. (2007). Endometrial regenerative cells: a novel stem cell population. Journal of Translational Medicine, 5, 57.
Borlongan, C. V., Kaneko, Y., Maki, M., Yu, S.-J., Ali, M., Allickson, J. G., Sanberg, C. D., Kuzmin-Nichols, N., & Sanberg, P. R. (2010). Menstrual blood cells display stem cell–like phenotypic markers and exert neuroprotection following transplantation in experimental stroke. Stem Cells and Development, 19, 439–452.
Patel, A. N., Park, E., Kuzman, M., Benetti, F., Silva, F. J., & Allickson, J. G. (2008). Multipotent menstrual blood stromal stem cells: Isolation, characterization, and differentiation. Cell Transplantation, 17, 303–311.
Shokri, M. R., Bozorgmehr, M., Ghanavatinejad, A., Falak, R., Aleahmad, M., Kazemnejad, S., Shokri, F., & Zarnani, A. H. (2019). Human menstrual blood-derived stromal/stem cells modulate functional features of natural killer cells. Scientific Reports, 9(1), 10007.
Rajabi, Z., Yazdekhasti, H., Mugahi, S. M. H. N., Abbasi, M., Kazemnejad, S., Shirazi, A., Majidi, M., & Zarnani, A. H. (2018). Mouse preantral follicle growth in 3D co-culture system using human menstrual blood mesenchymal stem cell. Reproductive Biology, 18(1), 122–131.
Bhartiya, D., & Patel, H. (2018). Ovarian stem cells-resolving controversies. Journal of Assisted Reproduction and Genetics, 35, 393–398.
Bhartiya, D. (2018). Stem cells survive oncotherapy & can regenerate non-functional gonads: A paradigm shift for oncofertility. Indian Journal of Medical Research, 148(Suppl 1), S38–S49.
Ye, H., Zheng, T., Li, W., Li, X., Fu, X., Huang, Y., Hu, C., Li, J., Huang, J., Liu, Z., & Zheng, L. (2017). Ovarian stem cell nests in reproduction and ovarian aging. Cellular Physiology and Biochemistry, 43(5), 1917–1925.
Asgari, H. R., Akbari, M., Yazdekhasti, H., Rajabi, Z., Navid, S., Aliakbari, F., Abbasi, N., Aval, F. S., Shams, A., & Abbasi, M. (2017). Comparison of human amniotic, chorionic, and umbilical cord multipotent mesenchymal stem cells regarding their capacity for differentiation toward female germ cells. Cellular Reprogramming (Formerly" Cloning and Stem Cells"), 19(1), 44–53.
Acknowledgments
The authors would like to appreciate Dr.Mohammad-Reza Sadeghi (Chairman of Avicenna Research Institute), Dr. Ali Sadeghi-Tabar (Managing director of Avicenna Infertility Clinic), Miss. Haleh Edalatkhah (Quality Control Assistant), Mrs. Somayeh Khorasani (production line assistant), Mrs. Zohreh Fathi (supervisor of embryology lab) and Mrs. Fariba Mohammadi (supervisor of operation room) for their assistance in implementation of this project.
Funding
This study was financially supported by Avicenna Research Institute (grant number: 960110–029).
Author information
Authors and Affiliations
Contributions
Simin Zafardoust: As a gynaecologist, part of study design, selection and randomization of patients, stem cell injection into ovaries and follow up of participants were performed by her.
Somaieh Kazemnejad: Study design, supervision of entire cell production, quality control and administration along with manuscript writing and editing were performed by her.
Maryam Darzi: She had contribution in stem cell isolation, culture and characterization.
Mina Fathi-Kazerooni: Quality Assurance manager.
Hilda Rastegari: Quality control of culture stem cells was implemented by her.
Afsaneh Mohammadzadeh: She had contribution in participant’s selection and their follow up after stem cell administration.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Ethics Approval
The study was started after providing complete information to patients and obtaining signed written consent. All the procedures in this clinical trial study were conducted according to the Declaration of Helsinki, Good Clinical Practice or good manufacturing practice (GMP) guideline approved by Biomedical Research Ethics Committee of Academic Center for Education, Culture and Research (ACECR, Tehran, Iran). The study was registered at the Iranian Registry of Clinical Trials (IRCT20180619040147N2). The cell manufacturing was performed by STERCO (Tehran, Iran) in GMP clean room authorized by Iran food and drug administration authorities.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Simin Zafardoust and Somaieh Kazemnejad are equally the first author
Electronic supplementary material
Supplementary Fig. 1
Flow chart of isolation, culture, expansion, banking, and infusion of Men-MSCs (JPG 1.42Â mb)
Supplementary Fig. 2
Morphology of menstrual blood stem cells in the first passage obtained from each participant in the cell therapy group. Scale bar: 300 μM (JPG 4.74 mb)
Supplementary Fig. 3
Immunophenotypic properties of cultured cells were assessed by flow cytometry. In brief, aliquots of 105 cells/100 μL were incubated separately with PE-conjugated anti-human CD73 (clone AD2; BD Pharmingen) or PE-conjugated anti human CD44 (clone 515;BD Pharmingen), CD90 (clone 5E10; BioLegend), CD45 (clone 2D1; BioLegend) for 30 min at 4 °C. Afterwards, all cell suspensions were washed twice with PBS-fetal bovine serum 2% and analyzed using a flow cytometer (Partec GmbH, Munster, Germany) using appropriate isotype controls. Representative histograms for CD markers of two samples (first participant and 15th participant) are demonstrated (gray). The respective isotype control is shown as black line. (JPG 614 kb)
ESM 4
(DOCX 47Â kb)
Rights and permissions
About this article
Cite this article
Zafardoust, S., Kazemnejad, S., Darzi, M. et al. Improvement of Pregnancy Rate and Live Birth Rate in Poor Ovarian Responders by Intraovarian Administration of Autologous Menstrual Blood Derived- Mesenchymal Stromal Cells: Phase I/II Clinical Trial. Stem Cell Rev and Rep 16, 755–763 (2020). https://doi.org/10.1007/s12015-020-09969-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12015-020-09969-6